Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Vacondio, Federica ^a   Bassi, Michele ^a   Silva, Claudia ^a   Castelli, Riccardo ^a   Carmi, Caterina ^a   Scalvini, Laura ^a   Lodola, Alessio ^a   Vivo, Valentina ^a   Flammini, Lisa ^a   Barocelli, Elisabetta ^a   Mor, Marco ^a   Rivara, Silvia ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(CYCLOHEXANELCARBOXYLOYLOXY)METHYL 2 (PALMITOYLAMINO)ETHYLCARBONATE; 1 (2 (PALMITOYLAMINO)ETHYL) N TERT BUTOXYCARBONYL O BENZYL LEUCYLASPARTATE; 1 [2 (PALMITOYLAMINO)ETHYL] O BENZYL LEUCYLASPARTATE; 2 (PALMITOYLAMINO)ETHYL ASPARTYLASPARAGINATE HYDROCHLORIDE; 2 (PALMITOYLAMINO)ETHYL ASPARTYLVALINATE HYDROCHLORIDE; 2 (PALMITOYLAMINO)ETHYL LEUCYLGLUTAMINATE HYDROCHLORIDE; 2 (PALMITOYLAMINO)ETHYL LEUCYLVALINATE HYDROCHLORIDE; 2 (PALMITOYLAMINO)ETHYL N TERT BUTOXYCARBONYL ASPARTYLASPARAGINATE; 2 (PALMITOYLAMINO)ETHYL N TERT BUTOXYCARBONYL ASPARTYLVALINATE; 2 (PALMITOYLAMINO)ETHYL N TERT BUTOXYCARBONYL LEUCYLALANINATE; 2 (PALMITOYLAMINO)ETHYL N TERT BUTOXYCARBONYL LEUCYLASPARAGINATE; 2 (PALMITOYLAMINO)ETHYL N TERT BUTOXYCARBONYL LEUCYLGLUTAMINATE; 2 (PALMITOYLAMINO)ETHYL N TERT BUTOXYCARBONYL LEUCYLISOLEUCINATE; 2 (PALMITOYLAMINO)ETHYL N TERT BUTOXYCARBONYL LEUCYLTRYPTOPHANATE; 2 (PALMITOYLAMINO)ETHYL N TERT BUTOXYCARBONYL LEUCYLVALINATE; 2 (PALMITOYLAMINO)ETHYLLEUCYLISOLEUCINATE HYDROCHLORIDE; 2 (PALMITOYLAMINO)ETHYLLEUCYLTRYPTOPHANATE HYDROCHLORIDE; 4 NITROPHENYL 2 (PALMITOYLAMINO)ETHYLCARBONATE; ACETOXYMETHYL 2 (PALMITOYLAMINO)ETHYLCARBONATE; AMINO ACID DERIVATIVE; CARBAMIC ACID DERIVATIVE; CARBONIC ACID; CHLOROMETHYL CARBONATE ESTER; ESTER DERIVATIVE; ISOBUTYROYLOXYMETHYL 2 (PALMITOYLAMINO)ETHYLCARBONATE; N (2 PALMITOYLAMINO ETHYLOXY)CARBONYL LEUCYLALANINE; N (2 PALMITOYLAMINO ETHYLOXY)CARBONYL LEUCYLVALINE; PALMIDROL; PRODRUG; UNCLASSIFIED DRUG; UNINDEXED DRUG; AMIDASE; AMINO ACID; ENZYME INHIBITOR; ESTER; ETHANOLAMINE DERIVATIVE; FATTY-ACID AMIDE HYDROLASE; PALMITIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; LIVER HOMOGENATE; MALE; NONHUMAN; PH MEASUREMENT; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMISTRY; METABOLISM; SYNTHESIS; WISTAR RAT;

RATTUS;

AMIDOHYDROLASES; AMINO ACIDS; ANIMALS; ENZYME INHIBITORS; ESTERS; ETHANOLAMINES; MALE; PALMITIC ACIDS; PRODRUGS; RATS, WISTAR;

EID: 84936804248     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128699     Document Type: Article

References (53)

1. Piomelli D, Sasso O. Peripheral gating of pain signals by endogenous lipid mediators. Nature Neurosci. 2014; 17: 164-174. doi: 10.1038/nn.3612 PMID: 24473264
2. Desarnaud F, Cadas H, Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J Biol Chem. 1995; 270: 6030-6035. PMID: 7890734
3. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996; 384: 83-87. PMID: 8900284
4. Ueda N, Yamanaka K, Yamamoto S. Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem. 2001; 276: 35552-35557. PMID: 11463796
5. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005; 67: 15-19. PMID: 15465922
6. Van Der Stelt M, Di Marzo V. Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem. 2004; 271: 1827-1834. PMID: 15128293
7. Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol. 1996; 300: 227-236. PMID: 8739213
8. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 1998; 394: 277-281. PMID: 9685157
9. Calignano A, La Rana G, Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol. 2001; 419: 191-198. PMID: 11426841
10. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 1998; 76: 189-199. PMID: 9696473
11. Lo Verme J, Gaetani S, Fu J, Oveisi F, Burton K, Piomelli D. Regulation of food intake by oleoylethanolamide. Mol Life Sci. 2005; 62: 708-716. PMID: 15770421
12. Solorzano C, Zhu C, Battista N, Astarita G, Lodola A, Rivara S, et al. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A. 2009; 106: 20966-20971. doi: 10.1073/pnas.0907417106 PMID: 19926854
13. Balvers MG, Verhoeckx KC, Meijerink J, Wortelboer HM, Witkamp RF. Measurement of palmitoylethanolamide and other N-acylethanolamines during physiological and pathological conditions. CNS Neurol Disord Drug Targets. 2013; 12: 23-33. PMID: 23394528
14. Petrosino S, Schiano A Moriello, Cerrato S, Fusco M, Puigdemont A, De Petrocellis L, Di Marzo V. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. Br J Pharmacol. 2015. doi: 10.1111/bph.13084
15. Cerrato S, Brazis P, della Valle MF, Miolo A, Petrosino S, Di Marzo V, et al. Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. Vet J. 2012; 191: 377-382. doi: 10.1016/j.tvjl.2011.04.002 PMID: 21601500
16. Della Valle F, Marcolongo G, Della Valle MF, inventors; Della Valle F, Marcolongo G, Della Valle MF, assignee. Composition containing ultra-micronized palmitoyl-ethanolamide. United States patent US8470373. 2013 Jun 25.
17. Duranti A, Tontini A, Antonietti F, Vacondio F, Fioni A, Silva C, et al. N-(2-oxo-3-oxetanyl)carbamic acid esters as N-acylethanolamine acid amidase inhibitors: synthesis and structure-activity and structure-property relationships. J Med Chem. 2012; 55: 4824-4836. doi: 10.1021/jm300349j PMID: 22515328
18. Russo R, Loverme J, La Rana G, Compton TR, Parrott J, Duranti A, et al. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther. 2007; 322: 236-242. PMID: 17412883
19. Fleisher D, Bong R, Stewart BH. Improved oral drug delivery: solubility limitations overcome by the use of prodrugs. Adv Drug Deliv Rev. 1996; 19: 115-130.
20. Oh DM, Han HK, Amidon GL. Drug transport and targeting. Intestinal transport. Pharm Biotechnol. 1999; 12: 59-88. PMID: 10742972
21. Produgs and drug delivery systems. In: Silverman RB, Holladay MW, editors. The organic chemistry of drug design and drug action, 3rd edition. San Diego: Elsevier Academic Press; 2014. pp. 423-468.
22. Luongo E, Russo R, Avagliano C, Santoro A, Melisi D, Orefice NS, et al. Galactosyl prodrug of palmitoylethanolamide: synthesis, stability, cell permeation and cytoprotective activity. Eur J Pharm Sci. 2014; 62: 33-39. doi: 10.1016/j.ejps.2014.05.009 PMID: 24854456
23. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother. 1995; 39: 2759-2764. PMID: 8593015
24. Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V, Ganapathy ME. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000; 89: 781-789. PMID: 10824137
25. Vig BS, Lorenzi PJ, Mittal S, Landowski CP, Shin HC, Mosberg HI, et al. Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm Res. 2003; 20: 1381-1388. PMID: 14567631
26. Song X, Lorenzi PL, Landowski CP, Vig BS, Hilfinger JM, Amidon GL. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol Pharm. 2005; 2: 157-167. PMID: 15804190
27. Vacondio F, Silva C, Mor M, Testa B. Qualitative structure-metabolism relationships in the hydrolysis of carbamates. Drug Metab Rev. 2010; 42: 551-589. doi: 10.3109/03602531003745960 PMID: 20441444
28. Wadkins RM, Morton CL, Weeks JK, Oliver L, Wierdl M, Danks MK, et al. Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases. Mol Pharmacol. 2001; 60: 355-362. PMID: 11455023
29. Buchwald P, Bodor N. Quantitative structure-metabolism relationships: steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters. J Med Chem. 1999; 42: 5160-5168. PMID: 10602701
30. Hong SY, Oh JE, Lee KH. Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. Biochem Pharmacol. 1999; 58: 1775-1780. PMID: 10571252
31. Tsume Y, Incecayir T, Song X, Hilfinger JM, Amidon GL. The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability. Eur J Pharm Biopharm. 2014; 86: 514-523. doi: 10.1016/j.ejpb.2013.12.009 PMID: 24361461
32. Ichikawa T, Kitazaki T, Matsushita Y, Yamada M, Hayashi R, Yamaguchi M, et al. Optically active antifungal azoles. XII. Synthesis and antifungal activity of the water-soluble prodrugs of 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl) phenyl]-2-imidazolidinone. Chem Pharm Bull. 2001; 49: 1102-1109. PMID: 11558595
33. Acedo M, Albericio F, Eritja R, N-2-(2,4-dinitrophenyl)ethyloxycarbonyl-amino acids, new base labile protected derivatives suitable for solid-phase peptide synthesis. Tetrahedron Lett. 1992; 33: 4989-4992.
34. Bennion C, Connolly S, Gensmantel NP, Hallam C, Jackson CG, Primrose WU, et al. Design and synthesis of some substrate analogue inhibitors of phospholipase A2 and investigations by NMR and molecular modeling into the binding interactions in the enzyme-inhibitor complex. J Med Chem. 1992; 35: 2939-2951. PMID: 1501221
35. Moreno-Sanz G, Sasso O, Guijarro A, Oluyemi O, Bertorelli R, Reggiani A, et al. Pharmacological characterization of the peripheral FAAH inhibitor URB937 in female rodents: interaction with the Abcg2 transporter in the blood-placenta barrier. Br J Pharmacol. 2012; 167: 1620-1628. doi: 10.1111/j.1476-5381.2012.02098.x PMID: 22774772
36. Diehl DH, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D, et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes, J Appl Toxicol. 2001; 21: 15-23. PMID: 11180276
37. Usansky JI, Desai A, Tang-Liu D, PK Functions for Microsoft Excel, Irvine, CA, 2001.
38. Schrödinger Suite 2013-3 Protein Preparation Wizard;
39. Epik version 2.6, Schrödinger, LLC, New York, NY, 2013;
40. Impact version 6.1, Schrödinger, LLC, New York, NY, 2013;
41. Prime version 3.4, Schrödinger, LLC, New York, NY, 2013.
42. Maestro, version 9.6, Schrödinger, LLC, New York, NY, 2013.
43. Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B. 2001; 105: 6474-6487.
44. Glide, version 6.1, Schrödinger, LLC, New York, NY, 2013.
45. MacroModel, version 10.2, Schrödinger, LLC, New York, NY, 2013.
46. Liederer BM, Borchardt RT. Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci. 2006; 95: 1177-1195. PMID: 16639719
47. Rivara M, Vacondio F, Silva C, Zuliani V, Fantini M, Bordi F, et al. Synthesis and stability in biological media of 1H-imidazole-1-carboxylates of ROS203, an antagonist of the histamine H3 receptor. Chem Biodives. 2008; 5: 140-152.
48. Vacondio F, Silva C, Lodola A, Carmi C, Rivara S, Duranti A, et al. Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability. Eur J Med Chem. 2011; 46: 4466-4473. doi: 10.1016/j.ejmech.2011.07.021 PMID: 21820769
49. Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, et al. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev. 2006; 12: 21-38. PMID: 16834756
50. Zhang D, Saraf A, Kolasa T, Bhatia P, Zheng GZ, Patel M, et al. Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets. Neuropharmacology. 2007; 52: 1095-1105. PMID: 17217969
51. Clapper JR, Vacondio F, King AR, Duranti A, Tontini A, Silva C, et al. A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo. ChemMedChem. 2009; 4: 1505-1513. doi: 10.1002/cmdc.200900210 PMID: 19637155
52. Astarita G, Di Giacomo B, Gaetani S, Oveisi F, Compton TR, Rivara S, et al. Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. J Pharmacol Exp Ther. 2006; 318: 563-570. PMID: 16702440
53. Bracey MH, Hanson MA, Masuda KR, Stevens RC, Cravatt BF. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science. 2002; 298: 1793-1796. PMID: 12459591